18-Sep-2023    Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection  
 
26-May-2023    A phase I/II trial of NOX66 in combination with nivolumab in patients with advanced cancer  
 
15-Nov-2022    CRO-67 is a Novel Therapeutic for Pancreatic Cancer: Implications for Tumour and Stromal Reprogramming  
 
27-May-2022    Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.  

Read More here.

 		 
24-May-2022    Noxopharm collaborators Hudson Institute of Medical Research confirm the relevance of TLR7 activation in Lupus  
 
27-Apr-2022    Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors  

Read More here.

 		 
8-Apr-2022    The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.  

177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

 		 
21-Jun-2021    Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides  
 
18-Nov-2020    Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma  
 
11-Aug-2020    Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer  
 
27-Jul-2020    Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists  
 
12-Nov-2019    LuPIN Data Being Presented To Conference  
 
12-Nov-2019    DARRT-1 Interim Data Presented To Conference  
 
21-Jun-2019    Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA  
 
13-Nov-2018    Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study  

Poster at COSA Annual Meeting Perth November 2018

 		 
13-Nov-2018    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

Poster at COSA Annual Meeting Perth November 2018

 		 
9-Jul-2018    NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study  

Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

 		 
5-Jun-2018    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  
 
6-Mar-2018    NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results  
 
20-Nov-2017    NOX66 Plus Carboplatin - Phase 1 Signalling Study  
 
13-Nov-2017    Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study  
 
13-Nov-2017    Idronoxil levels of patients receiving NOX66  
 
13-Nov-2017    ENOX2 levels of patients receiving NOX66  
 
11-Sep-2017    Chemosensitization of Carboplatin by NOX66